Anthropometry (3)
- BMI - Body mass index (phv00388820.v1.p1)
- height - Height (phv00388818.v1.p1)
- weight - Weight (phv00388819.v1.p1)
Demographics (2)
- age - Age (phv00388817.v1.p1)
- sex - Sex (phv00388816.v1.p1)
Disease Events (2)
- AFFECTION_STATUS - Case control status for bevacizumab-induced hypertension (phv00388812.v1.p1)
- diabetes - History of diabetes at baseline (phv00388822.v1.p1)
Race and Ethnicity (2)
- ethnicity - Ethnicity (phv00388815.v1.p1)
- race - Race (phv00388814.v1.p1)
Other (13)
- ANALYTE_TYPE - Analyte type (phv00388825.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00388824.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00388803.v1.p1)
- cycle - Treatment cycle of maximum grade hypertension event (phv00388813.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00388827.v1.p1)
- IS_TUMOR - Tumor status (phv00388826.v1.p1)
- PRHPT - History of hypertension at baseline (phv00388821.v1.p1)
- SAMPLE_ID - De-identified sample ID (phv00388823.v1.p1)
- SAMPLE_ID - Sample ID (phv00388807.v1.p1)
- SAMPLE_USE - Sample Use (phv00388810.v1.p1)
- SUBJECT_ID - De-identified subject ID (phv00388811.v1.p1)
- SUBJECT_ID - Subject ID (phv00388806.v1.p1)
- SUBJECT_ID - Subject ID (phv00388802.v1.p1)